Literature DB >> 16952681

Bringing prostate cancer quality of life research back to the bedside: translating numbers into a format that patients can understand.

James A Talcott1, Jack A Clark, Judith Manola, Sonya P Mitchell.   

Abstract

PURPOSE: Although measuring quality of life of patients with prostate cancer serves important research goals, its primary clinical purpose is informing patients. Sophisticated quality of life measures produce purely numerical results that patients have difficulty understanding. We present an approach that preserves the methodological strengths of validated multi-item measures but provides more accessible information for clinical use.
MATERIALS AND METHODS: Using validated indexes measuring urinary, bowel and sexual function we surveyed patients with clinically localized prostate cancer before treatment and at intervals thereafter. Based on patient responses to parallel distress measures we defined 3 levels of function, including normal-no abnormal symptom, intermediate-any abnormal symptom but none severely abnormal and poor-any severely abnormal symptom. We then translated patient survey results into these levels. To assess measurement properties we compared average symptom distress scores in patients at each symptom level.
RESULTS: Levels of function and patient distress scores correlated strongly. Large and approximately equal differences in distress scores separated patients at successive levels in all symptom indexes (effect size greater than 1.2, p < 0.0001). Using these categories we created tables showing 24-month outcomes in 417 previously reported patients by pretreatment symptom level and treatment, providing a tool for patients to determine posttreatment outcomes in similar patients.
CONCLUSIONS: Using symptom indexes to define levels of function produces a quality of life metric that is valid, defines quantitative intervals, is transparent and may be more useful to patients. This approach provides methodologically sound outcome information to patients attempting to choose a prostate cancer treatment.

Entities:  

Mesh:

Year:  2006        PMID: 16952681     DOI: 10.1016/j.juro.2006.06.067

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  7 in total

1.  Long-Term Patient-Reported Outcomes From a Phase 3 Randomized Prospective Trial of Conventional Versus Hypofractionated Radiation Therapy for Localized Prostate Cancer.

Authors:  Talha Shaikh; Tianyu Li; Elizabeth A Handorf; Matthew E Johnson; Lora S Wang; Mark A Hallman; Richard E Greenberg; Robert A Price; Robert G Uzzo; Charlie Ma; David Chen; Daniel M Geynisman; Alan Pollack; Eric M Horwitz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-12-28       Impact factor: 7.038

Review 2.  Recommended patient-reported core set of symptoms to measure in prostate cancer treatment trials.

Authors:  Ronald C Chen; Peter Chang; Richard J Vetter; Himansu Lukka; William A Stokes; Martin G Sanda; Deborah Watkins-Bruner; Bryce B Reeve; Howard M Sandler
Journal:  J Natl Cancer Inst       Date:  2014-07-08       Impact factor: 13.506

3.  Patient-reported sexual quality of life after different types of radical prostatectomy and radiotherapy: Analysis of a population-based prospective cohort.

Authors:  Brandon T Mullins; Ramsankar Basak; James R Broughman; Ronald C Chen
Journal:  Cancer       Date:  2019-06-30       Impact factor: 6.860

4.  Association Between Choice of Radical Prostatectomy, External Beam Radiotherapy, Brachytherapy, or Active Surveillance and Patient-Reported Quality of Life Among Men With Localized Prostate Cancer.

Authors:  Ronald C Chen; Ramsankar Basak; Anne-Marie Meyer; Tzy-Mey Kuo; William R Carpenter; Robert P Agans; James R Broughman; Bryce B Reeve; Matthew E Nielsen; Deborah S Usinger; Kiayni C Spearman; Sarah Walden; Dianne Kaleel; Mary Anderson; Til Stürmer; Paul A Godley
Journal:  JAMA       Date:  2017-03-21       Impact factor: 56.272

5.  Prostate Cancer Patient Characteristics Associated With a Strong Preference to Preserve Sexual Function and Receipt of Active Surveillance.

Authors:  James R Broughman; Ramsankar Basak; Matthew E Nielsen; Bryce B Reeve; Deborah S Usinger; Kiayni C Spearman; Paul A Godley; Ronald C Chen
Journal:  J Natl Cancer Inst       Date:  2018-04-01       Impact factor: 13.506

6.  Fitting NTCP models to bladder doses and acute urinary symptoms during post-prostatectomy radiotherapy.

Authors:  Panayiotis Mavroidis; Kevin A Pearlstein; John Dooley; Jasmine Sun; Srinivas Saripalli; Shiva K Das; Andrew Z Wang; Ronald C Chen
Journal:  Radiat Oncol       Date:  2018-02-02       Impact factor: 3.481

7.  Long-term quality of life after definitive treatment for prostate cancer: patient-reported outcomes in the second posttreatment decade.

Authors:  Joanne W Jang; Michael R Drumm; Jason A Efstathiou; Jonathan J Paly; Andrzej Niemierko; Marek Ancukiewicz; James A Talcott; Jack A Clark; Anthony L Zietman
Journal:  Cancer Med       Date:  2017-05-31       Impact factor: 4.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.